FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2093433243> ?p ?o ?g. }

• W2093433243 endingPage "833" @default.
• W2093433243 startingPage "825" @default.
• W2093433243 abstract "Replacement of calcineurin inhibitor (CI) with anti-metabolic agents in transplant patients with CI-induced nephrotoxicity is performed clinically and improves renal function, but increases the risk of rejection. We investigated whether the change from cyclosporine (CsA) to a limited dose of mycophenolic acid (MPA) together with a new sphingosine-1-phosphate (S1P) receptor agonist, KRP-203, is sufficient to prevent both transplant vasculopathy and CsA-induced nephrotoxicity.Orthotopic aortic transplantation was conducted in a high-responder rat combination of Dark Agouti (DA; major histocompatibility complex [MHC] haplotype RT-1a) to Lewis (RT-1(l)). After CsA administration (15 mg/kg/day) for 2 weeks, the recipients were divided into the following treatment groups for 6 weeks: MPA (10 mg/kg); KRP-203 (KRP; 1 mg/kg); and MPA + KRP. Serum creatinine (Cr), arteriolar hyalinosis and expression of transforming growth factor (TGF)-beta1 in the recipient kidney were examined as parameters indicating nephrotoxicity. Intimal hyperplasia was assessed by vascular occlusion, and graft-infiltrated cells were semi-quantitatively evaluated histologically and then characterized immunohistochemically.Continuous CsA treatment attenuated intimal hyperplasia and cell infiltration (2.9 +/- 0.3% and 0.4 +/- 0.1; p < 0.01 vs vehicle), but increased Cr and hyalinosis (0.43 +/- 0.03 mg/dl and 57.2 +/- 0.4%; p < 0.01) with upregulated TGF-beta1. Replacement of CsA by MPA or KRP treatment alone improved nephrotoxicity, but worsened intimal hyperplasia and cell infiltration. Conversion to MPA + KRP treatment prevented nephrotoxicity (Cr, 0.32 +/- 0.02 mg/dl; hyalinosis, 5.6 +/- 1.3%; p < 0.01 vs CsA) and markedly suppressed intimal hyperplasia and cell infiltration (3.6 +/- 1.2% and 1.0 +/- 0.3; p = not significant vs CsA), with reduced T-cell infiltrates in the graft.Changing from CsA to a combined therapy of MMF with S1P agonist is a promising strategy in clinical transplantation to overcome CI-induced nephrotoxicity and chronic rejection." @default.
• W2093433243 created "2016-06-24" @default.
• W2093433243 creator A5003507714 @default.
• W2093433243 creator A5011177568 @default.
• W2093433243 creator A5018252207 @default.
• W2093433243 creator A5033874723 @default.
• W2093433243 creator A5038910607 @default.
• W2093433243 creator A5058137680 @default.
• W2093433243 creator A5060520190 @default.
• W2093433243 creator A5062932502 @default.
• W2093433243 creator A5081289778 @default.
• W2093433243 date "2006-07-01" @default.
• W2093433243 modified "2023-10-01" @default.
• W2093433243 title "Change From Cyclosporine to Combination Therapy of Mycophenolic Acid With the New Sphingosine-1-phosphate Receptor Agonist, KRP-203, Prevents Host Nephrotoxicity and Transplant Vasculopathy in Rats" @default.
• W2093433243 cites W1945701558 @default.
• W2093433243 cites W1964101426 @default.
• W2093433243 cites W1967642852 @default.
• W2093433243 cites W1998535208 @default.
• W2093433243 cites W1999093674 @default.
• W2093433243 cites W2001573471 @default.
• W2093433243 cites W2003655983 @default.
• W2093433243 cites W2007849357 @default.
• W2093433243 cites W2007946393 @default.
• W2093433243 cites W2009289522 @default.
• W2093433243 cites W2014724606 @default.
• W2093433243 cites W2018595886 @default.
• W2093433243 cites W2019626836 @default.
• W2093433243 cites W2026266404 @default.
• W2093433243 cites W2028077117 @default.
• W2093433243 cites W2031840858 @default.
• W2093433243 cites W2033032006 @default.
• W2093433243 cites W2033567610 @default.
• W2093433243 cites W2034953095 @default.
• W2093433243 cites W2035881418 @default.
• W2093433243 cites W2049191601 @default.
• W2093433243 cites W2051143996 @default.
• W2093433243 cites W2052667900 @default.
• W2093433243 cites W2065528440 @default.
• W2093433243 cites W2068181630 @default.
• W2093433243 cites W2072588728 @default.
• W2093433243 cites W2083114532 @default.
• W2093433243 cites W2085575696 @default.
• W2093433243 cites W2089310747 @default.
• W2093433243 cites W2096193471 @default.
• W2093433243 cites W2103080635 @default.
• W2093433243 cites W2122563088 @default.
• W2093433243 cites W2123444566 @default.
• W2093433243 cites W2134672034 @default.
• W2093433243 cites W2138045546 @default.
• W2093433243 cites W2151119404 @default.
• W2093433243 cites W2151248872 @default.
• W2093433243 cites W2151625079 @default.
• W2093433243 cites W2168638212 @default.
• W2093433243 cites W2171777999 @default.
• W2093433243 doi "https://doi.org/10.1016/j.healun.2006.03.014" @default.
• W2093433243 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16818126" @default.
• W2093433243 hasPublicationYear "2006" @default.
• W2093433243 type Work @default.
• W2093433243 sameAs 2093433243 @default.
• W2093433243 citedByCount "11" @default.
• W2093433243 countsByYear W20934332432012 @default.
• W2093433243 countsByYear W20934332432014 @default.
• W2093433243 countsByYear W20934332432016 @default.
• W2093433243 crossrefType "journal-article" @default.
• W2093433243 hasAuthorship W2093433243A5003507714 @default.
• W2093433243 hasAuthorship W2093433243A5011177568 @default.
• W2093433243 hasAuthorship W2093433243A5018252207 @default.
• W2093433243 hasAuthorship W2093433243A5033874723 @default.
• W2093433243 hasAuthorship W2093433243A5038910607 @default.
• W2093433243 hasAuthorship W2093433243A5058137680 @default.
• W2093433243 hasAuthorship W2093433243A5060520190 @default.
• W2093433243 hasAuthorship W2093433243A5062932502 @default.
• W2093433243 hasAuthorship W2093433243A5081289778 @default.
• W2093433243 hasConcept C126189478 @default.
• W2093433243 hasConcept C126322002 @default.
• W2093433243 hasConcept C126894567 @default.
• W2093433243 hasConcept C128057223 @default.
• W2093433243 hasConcept C170493617 @default.
• W2093433243 hasConcept C2776999253 @default.
• W2093433243 hasConcept C2778033501 @default.
• W2093433243 hasConcept C2778653478 @default.
• W2093433243 hasConcept C2778938600 @default.
• W2093433243 hasConcept C2779458710 @default.
• W2093433243 hasConcept C2780091579 @default.
• W2093433243 hasConcept C2780303639 @default.
• W2093433243 hasConcept C2780306776 @default.
• W2093433243 hasConcept C2909675724 @default.
• W2093433243 hasConcept C2911091166 @default.
• W2093433243 hasConcept C71924100 @default.
• W2093433243 hasConcept C98274493 @default.
• W2093433243 hasConceptScore W2093433243C126189478 @default.
• W2093433243 hasConceptScore W2093433243C126322002 @default.
• W2093433243 hasConceptScore W2093433243C126894567 @default.
• W2093433243 hasConceptScore W2093433243C128057223 @default.
• W2093433243 hasConceptScore W2093433243C170493617 @default.
• W2093433243 hasConceptScore W2093433243C2776999253 @default.
• W2093433243 hasConceptScore W2093433243C2778033501 @default.
• W2093433243 hasConceptScore W2093433243C2778653478 @default.

• next